Efficacy and Atypicals: It’s Hand-to-Hand Combat
The Carlat Psychiatry Report, Volume 2, Number 2, February 2004
https://www.thecarlatreport.com/newsletter-issue/tcprv2n2/
From The Carlat Psychiatry Report, February 2004, Battle of the Atypicals
Issue Links: | Editorial Information
Daniel Carlat, MD
Dr. Carlat has disclosed that he has no significant relationships with or financial interests in any commercial companies pertaining to this educational activity.
Things were bound to get ugly. The total market for antipsychotics is $10 billion, there are five very similar atypicals jockeying for an extra nibble of that huge pie, and each atypical is backed by an aggressive pharmaceutical firm. You do the math.
You can't view details of this content, please login or buy subscription here